Skip to main content

Huston Associates, LLC

Scientific & Market Driven Biopharmaceutical Development Planning and Execution
Home
About Us
Biography
Industry Experience
Publications
Contact Us
Site Map

Product Development and Operations Experience:

 

Proleukin - IL2 (Nonclinical, IND)

 

 

Betaseron®

(Phase 2-3, PLA/ELA, Market Launch, Established          academic research program in Multiple Sclerosis)

 

 

Enbrel® (Phase 2, 3)

 

 

Actimmune® (Phase 2,3, BLA, new INDs)

 

 

IL-4 Receptor (Phase 2, Corporate partner)

 

IL-1 Receptor (Phase 2, Corporate partners)

 

T-cell Receptor (Phase 2, out-license)

 

ConXn® Relaxin (Phase 2)

 

Luxiq® (Phase 3, 505b2 NDA, Market Launch)

Olux® (Phase 1-2)

 

Fludara® (Market Launch)

 

 

Thioplex® (NDA, Market Launch)

 

 

Mitomycin C (out-license, Corporate partner)

 

 

Etoposide (out-license, Corporate partner)

 

 

Leucovorin Calcium (ANDA)

 

Adefovir dipivoxil - Hepsera® (Phase 3) 

Tenofovir disoproxil -Viread® (Phase 2, 3)

 

Vaccine Adjuvants (Discovery, IND, Phase1)

 

Ziconotide (Phase 3, NDA, MAA, Launch)

 

Ceftazidime/Avibactam (Phase 3, NDA)

 

Therapeutic Areas:

 

Autoimmunity/Inflammation

Multiple Sclerosis

Scleroderma

Rheumatoid Arthritis

Crohns’ Disease

Asthma

Oncology

Breast Cancer

Colorectal Cancer

Glioma

Malignant Melanoma

Ovarian Cancer

Prostate Cancer

Renal Cell Carcinoma

Small-cell Lung Cancer

 

 

 

 

 

 

Metabolic Kidney Disease

Chronic Pain

Dermatology

 

Infectious Diseases

Anti-virals (HIV, Hepatitis B & C)

Antibiotics

 

Gene Therapy

     Hemophilia

     Parkinson's Disease